Lee's Pharmaceutical Holdings Limited (HK:0950)
:0950
Want to see HK:0950 full AI Analyst Report?
Top Page
Lee's Pharmaceutical Holdings Limited
(0950)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$1.00
▼(-35.48% Downside)
Action:ReiteratedDate:04/27/26
The score is supported mainly by an attractive valuation (low P/E and solid dividend yield) and a stable, low-leverage balance sheet. Offsetting this are inconsistent operating results with 2025 margin pressure and volatile free cash flow, plus a clearly bearish technical trend with weak momentum.
Positive Factors
Conservative Balance Sheet
Low leverage and rising equity give the company financial resilience. Conservative debt-to-equity (~0.08–0.15) and an expanding capital base reduce refinancing and liquidity risk, enabling steady funding of R&D, licensing deals and commercial operations over the medium term.
Negative Factors
Volatile Revenue Trends
Top-line volatility — a 33% rebound in 2024 followed by a 3% decline in 2025 — indicates inconsistent product demand or lumpy milestone recognition. Such swings complicate forecasting, resource allocation and stable growth planning over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and rising equity give the company financial resilience. Conservative debt-to-equity (~0.08–0.15) and an expanding capital base reduce refinancing and liquidity risk, enabling steady funding of R&D, licensing deals and commercial operations over the medium term.
Read all positive factors
Lee's Pharmaceutical Holdings Limited (0950) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$659.50M
Dividend Yield2.92%
Average Volume (3M)5.40M
Price to Earnings (P/E)9.7
Beta (1Y)0.65
Revenue Growth2.57%
EPS Growth-1.27%
CountryHK
Employees1,022
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.04
Shares Outstanding588,835,300
10 Day Avg. Volume4,101,801
30 Day Avg. Volume5,400,283
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.44
Price to Sales (P/S)0.62
P/FCF Ratio8.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lee's Pharmaceutical Holdings Limited Business Overview & Revenue Model
Company Description
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovas...
How the Company Makes Money
Lee's Pharmaceutical makes money primarily by commercializing prescription pharmaceutical products. Key revenue streams typically include: (1) product sales revenue from medicines it markets in its target markets (notably Mainland China) through i...
Lee's Pharmaceutical Holdings Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
74
Positive
Cash Flow
48
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.44B | 1.40B | 1.05B | 1.23B | 1.27B |
| Gross Profit | 729.56M | 753.36M | 551.31M | 770.75M | 806.28M |
| EBITDA | 217.13M | 260.87M | 193.05M | 229.06M | 2.13B |
| Net Income | 91.94M | 93.10M | 16.70M | 51.28M | 1.99B |
Balance Sheet | |||||
| Total Assets | 3.46B | 2.62B | 2.89B | 2.78B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 349.90M | 216.84M | 171.00M | 189.30M | 277.53M |
| Total Debt | 310.27M | 227.30M | 204.14M | 163.49M | 267.14M |
| Total Liabilities | 1.56B | 1.07B | 930.07M | 939.50M | 1.25B |
| Stockholders Equity | 2.05B | 1.65B | 2.04B | 1.92B | 2.46B |
Cash Flow | |||||
| Free Cash Flow | 101.35M | 34.45M | -49.63M | 69.81M | -160.04M |
| Operating Cash Flow | 332.90M | 242.01M | 110.08M | 283.63M | 210.68M |
| Investing Cash Flow | -235.76M | -190.23M | -145.22M | -256.05M | -370.28M |
| Financing Cash Flow | 35.58M | -1.96M | 13.44M | -128.60M | 60.97M |
Lee's Pharmaceutical Holdings Limited Technical Analysis
Negative
1.55
Price Trends
1.36
Negative
1.50
Negative
1.70
Negative
Market Momentum
-0.04
Negative
42.10
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0950, the sentiment is Negative. The current price of 1.55 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.36, and below the 200-day MA of 1.70, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0950.
Lee's Pharmaceutical Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$7.31B | 6.31 | 11.90% | 5.80% | -17.03% | 12.82% | |
72 Outperform | HK$1.70B | 7.90 | 6.34% | 5.16% | 16.09% | -62.16% | |
60 Neutral | HK$659.50M | 9.74 | 5.66% | 2.92% | 2.57% | -1.27% | |
58 Neutral | HK$9.43B | 30.68 | 5.62% | 4.47% | 3.34% | -39.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$12.32B | 34.17 | 3.49% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:0950
Lee's Pharmaceutical Holdings Limited
1.15
-0.15
-11.54%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.31
0.59
80.94%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.14
0.07
6.54%
HK:2877
China Shineway Pharmaceutical Group Limited
9.78
2.58
35.83%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.18
0.88
16.69%
Lee's Pharmaceutical Holdings Limited Corporate Events
Lee’s Pharmaceutical Sets 2026 AGM to Approve Results, Dividend and Capital Mandates
Apr 23, 2026
Lee’s Pharmaceutical Holdings Limited has convened its annual general meeting for 21 May 2026 in Hong Kong, where shareholders will review and approve the audited financial statements for the year ended 31 December 2025 and consider a final ...
Lee’s Pharmaceutical Declares Final Dividend for 2025
Mar 30, 2026
Lee’s Pharmaceutical Holdings Limited has declared a final ordinary dividend of HKD 0.023 per share for the financial year ended 31 December 2025, reinforcing its commitment to delivering cash returns to shareholders. The dividend, denominat...
Lee’s Pharmaceutical posts flat profit on higher costs, trims final dividend
Mar 30, 2026
Lee’s Pharmaceutical Holdings Limited reported a modest 2.6% increase in revenue to HK$1.44 billion for the year ended 31 December 2025, while gross profit slipped 3.2% to HK$729.6 million. Profit attributable to shareholders edged down 1.2%...
Lee’s Pharm Wins China Approval for Intrarosa, Bolstering Women’s Health Portfolio
Mar 25, 2026
Lee’s Pharmaceutical Holdings has secured Chinese regulatory approval for Intrarosa, a non-estrogen steroid therapy licensed from Cosette Pharmaceuticals for treating postmenopausal women with moderate to severe vulvovaginal atrophy symptoms...
Lee’s Pharmaceutical Sets March 2026 Board Meeting to Review 2025 Results
Mar 17, 2026
Lee’s Pharmaceutical Holdings has scheduled a board meeting on 30 March 2026 at its Hong Kong Science Park offices to review and approve the annual results for the year ended 31 December 2025. The board will also consider whether to recommen...
Lee’s Pharm Wins FDA Clearance for U.S. ADASUVE Manufacturing Shift
Jan 27, 2026
Lee’s Pharmaceutical Holdings Limited has secured U.S. Food and Drug Administration approval for a supplemental new drug application relating to ADASUVE (loxapine) Inhalation Powder, authorising the move of the drug’s commercial manufa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.